Risankizumab for psoriasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Apr 2021: Trial registered, NCT04862286
  2. 24 Jul 2021: Trial started, NCT04862286

The trials

NCT04862286: Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

State
Under way
Phase
Phase 3
People
132 planned
Started
24 Jul 2021
Primary completion
Apr 2028
Arms
Risankizumab
Results
None posted
  1. 27 Apr 2021: Trial registered
  2. 24 Jul 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as BI-655066.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.